

## Reinvigorating the Oral Antibacterial Drug Development Pipeline

The Brookings Institution • Washington, DC

Thursday, November 20, 2014

---

- 8:30 a.m.**      **Registration**
- 9:00 a.m.**      **Welcome and Introduction**  
Mark McClellan, The Brookings Institution  
Gregory Daniel, Engelberg Center for Health Care Reform at Brookings
- 9:15 a.m.**      **Identifying Priority Areas for Oral Antibacterial Drug Development**  
Edward Cox, U.S. Food and Drug Administration
- 9:30 a.m.**      **Session I: Challenges with Oral Antibacterial Drug Development**  
Mark McClellan - *Moderator*  
Sumathi Nambiar, U.S. Food and Drug Administration  
Helen Boucher, Tufts Medical Center  
Michael Dudley, The Medicines Company  
John Rex, AstraZeneca
- 10:30 a.m.**      **Break**
- 10:45 a.m.**      **Session II: Strategies to Support Oral Antibacterial Drug Development**  
Mark McClellan - *Moderator*  
John Powers, George Washington University School of Medicine  
Christine Ginocchio, bioMérieux  
Michael Dunne, Durata Therapeutics, Inc.
- 12:00 p.m.**      **Lunch**
- 1:00 p.m.**      **Session III: Economic Incentives to Catalyze Oral Antibacterial Drug Development**  
Mark McClellan - *Moderator*  
Jeffrey Kelman, Centers for Medicare & Medicaid Services  
Kevin Outterson, Boston University  
Steve Miller, Express Scripts, Inc.
- 2:20 p.m.**      **Recap and Closing Remarks**  
Mark McClellan
- 2:30 p.m.**      **Adjournment**